aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.
Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
Read more at globenewswire.com
